United States: Federal Circuit Vacates Infringement Of Braintree SUPREP Patent

In a divided opinion issued in Braintree Labs., Inc. v. Novel Labs., Inc., the Federal Circuit reversed the district court on one of two challenged claim construction issues and vacated the district court's finding of infringement to remand for further factual findings. When no judge agrees with the basis of the decision and neither party is satisfied with the outcome, what can we learn from this case?

The Patent at Issue

The patent at issue was Braintree's U.S. 6,946,149, which is listed in the Orange Book for its SUPREP® Bowel Prep Kit for preparing patients for colonoscopies. Reexamined claim 15 was treated as representative:

A composition for inducing purgation of the colon of a patient, the composition comprising from about 100 mL to about 500 mL of an aqueous hypertonic solution comprising an effective amount of Na2SO4, an effective amount of MgSO4, and an effective amount of K2SO4, wherein the composition does not produce any clinically significant electrolyte shifts and does not include phosphate.

According to the Federal Circuit decision, "Braintree sells SUPREP® in a kit containing two six-ounce bottles of concentrated solution, along with a dilution cup." To use the product, "[a] patient must dilute each of the two six-ounce bottles with ten ounces of water to form two sixteen-ounce solutions," each of which has a volume of 473 mL. Thus, Braintree's theory of infringement (and basis for listing the patent in the Orange Book for SUPREP®) is that one bottle of the two-bottle kit falls within the scope of the claims. The Federal Circuit decision refers to this as the "one bottle" theory of infringement.

The ANDA Litigation

Novel filed an ANDA seeking approval to market a generic version of SUPREP®, and making a paragraph IV certification against the '149 patent. In the ensuing ANDA litigation, the district court construed the claims, granted summary judgment of infringement, and upheld the validity of the patent after a bench trial.

The claim construction issues challenged on appeal related to the meaning of "purgation" and the meaning of "clinically significant electrolyte shifts." While not treated as an independent claim construction issue, the impact of the term "a patient" in the preamble also was important to the infringement issue.

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Prost. Judge Dyk wrote an opinion concurring-in-part, dissenting-in-part, and concurring in the result, while Judge Moore wrote a dissenting opinion. The judges appear to agree on the claim construction issues, but disagree on infringement and/or the "patient" issue.

"Purgation"

As noted by the Federal Circuit, "[t]he district court construed 'purgation' to mean 'an evacuation of a copious amount of stool from the bowels after oral administration of the solution.'" Novel argued that "purgation" should mean the type of complete "cleansing" required to permit visualization of the colon for a colonoscopy. The Federal Circuit disagreed, focusing on the plain language of the claims and interpreting "inducing purgation" as meaning "inducing diarrhea."

"clinically significant electrolyte shifts"

As noted by the Federal Circuit, the district court construed "'clinically significant electrolyte shifts'" to be 'alterations in blood chemistry that are both outside the normal upper or lower limits of their range and accompanied by or manifested as other untoward effects.'" The Federal Circuit reversed that claim construction, because the specification expressly defined the term as meaning "alterations in blood chemistry that are outside the normal upper or lower limits of their range or other untoward effects."

Infringement

The Federal Circuit decision vacates the district court's summary judgment of infringement. Judge Dyk concurred in that result, but believes that Novel established non-infringement as a matter of law because he disagrees with the "one bottle" theory of infringement. In contrast, Judge Moore dissents because she disagrees with Judge Prost's treatment of the "a patient" language.

The district court considered infringement from two perspectives:

  • does one bottle of SUPREP® induce purgation
  • does one bottle of SUPREP® avoid producing clinically significant electrolyte shifts

Judge Prost affirmed the district court's decision that one bottle of SUPREP® induces purgation, even though two bottles are required to prepare a patient for a colonoscopy. Judge Dyk disagrees with the "one bottle" theory of infringement because it is inconsistent with the product at issue in the ANDA. That is, because Novel's ANDA sought approval of a two-bottle product wherein the patient is administered a total volume of 946 mL, it could not infringe a claim reciting "a composition with a volume or 100-500 mL for inducing purgation and a method of using the same."

Judge Prost vacated the district court's summary judgment of infringement because there was a genuine issue of material fact as to whether SUPREP® avoids producing clinically significant electrolyte shifts in a patient population. While the district court interpreted the "clinically significant electrolyte shifts" clause in conjunction with the "a patient" referenced in the preamble as requiring that "at least one patient" not experience those effects, Judge Prost interpreted the claim as requiring that "a patient population" not experience those effects. Judge Moore disagrees with the collective view of the side effects clause, and finds that the specification indicates that "clinical significance is measured in an individual patient." Thus, she would have found the product to infringe even if only one patient out of 100 does not experience clinically significant electrolyte shift.

Non-Infringement in the ANDA Context

In the ANDA context, non-infringement is found if making, using, or selling the proposed generic product for use in accordance with the approved labeling does not infringe the Orange Book listed patent(s). In many cases, generic companies may be able to design around the patents in such a way that the generic product is somewhat different from the approved brand name product. In this case, however, Novel's proposed product appears to be identical to SUPREP®. Thus, a finding that Novel's ANDA does not infringe the patent would indicate that the Orange Book listed patent does not, in fact, cover the approved product and so should not have been listed in the Orange Book.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions